Gilead Sciences, Inc., Terumo Medical Corporation, and Getinge AB. dominated the U.S. Acute Respiratory Distress Syndrome (ARDS) Market in 2021

The U.S. Acute Respiratory Distress Syndrome (ARDS) Market is said to grow with a CAGR of 10.6% in the forecast period of 2022 to 2029. The years considered for the study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/us-acute-respiratory-distress-syndrome-ards-market

The U.S. acute respiratory distress syndrome (ARDS) market is a highly fragmented market, which includes a number of key players as well as local players. The market has witnessed increased strategic developments owing to a favorable market scenario.

The major players operating in the U.S. acute respiratory distress syndrome (ARDS) market are developing more advanced and innovative devices. They are exploring product innovations in the industry through strategic research and development activities, thereby enhancing their product offerings.

For instance,

• In May 2021, Medtronic launched SonarMed airway monitoring system. The system utilizes acoustic technology to check for endotracheal tube obstruction. This has helped the company to increase its product portfolio
• In January 2020, ResMed launched AirTouch N20 Foam CPAP Mask. Its Softest Nasal Mask Ever - ResMed’s first nasal memory foam cushion enhanced patients’ comfort and convenience. It didn’t need cleaning when replaced on an appropriate schedule. AirTouch N20 was the latest offering in ResMed’s line of easy-to-use, convenient, and more comfortable masks. This has helped the company to expand its product portfolio

Gilead Sciences, Inc. is the dominating player in the U.S. acute respiratory distress syndrome (ARDS) market. Some other key players in the market include Terumo Medical Corporation, Getinge AB., LivaNova P.L.C., Medtronic, NIPRO, Pfizer Inc., ResMed, among others.

Gilead Sciences, Inc.

Gilead Sciences, Inc. is headquartered in California, U.S., and was founded in 1987. It has public ownership. The company focuses on discovering and developing therapeutics for people with life-threatening diseases. The company offers a wide range of product categories such as HIV/AIDS, COVID-19, Liver Diseases, Hematology/Oncology, Cardiovascular, Inflammation/Respiratory, and Other Medicines Inflammation/Respiratory is the market-focused category.

• In July 2020, Gilead Sciences, Inc. initiated clinical testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19. This testing helped the company enhance its antiviral product portfolio, thereby strengthening its footprint on the market

The company has a wide global presence across Europe, Asia-Pacific, and North America with its various subsidiaries such as Asegua Therapeutics L.L.C. (U.S.), Forty Seven, Inc. (U.S.), Forty Seven Holdings, and L.L.C. (U.S.), Gilead Alberta, L.L.C. (U.S.), Gilead Apollo, LLC.(U.S.), Gilead Biopharmaceutics US LLC (U.S.), among others.

Terumo Corporation

Terumo Corporation is headquartered in Tokyo, Japan, and was founded in 1921. It has public ownership. The company focuses on giving a large portfolio of medical products for clinical practice. The company operates in various business segments, such as Cardiovascular Division, General Hospital, Blood and Cell Technologies, out of which Cardiovascular Division is the market-focused segment. The company offers a wide range of product categories such as Terumo Interventional Systems, Neurovascular Division, Cardiovascular Division, and Vascular Graft Division, in which Cardiovascular Division is the market-focused category.

• In April 2020, Terumo Corporation doubled the extracorporeal membrane oxygenation ECMO Production and Supply. ECMO consists of an oxygenator and centrifugal pump for patients with severe respiratory failure. This will help the company to increase its market growth in the market

The company has a wide global presence across Europe, the Middle East and Africa, Greater China, Asia, North America, and South America with its various subsidiaries such as Terumo BCT, Inc. (U.S.), MicroVention, Inc. (U.S.), Terumo Aortic Limited (U.K.), Terumo (Thailand) Co., Ltd. (Thailand), Terumo Penpol (India), among others.

Getinge AB

Getinge AB is headquartered in Gothenburg, Sweden, founded in 1904. It has public ownership. The company focuses on providing hospitals and life sciences institutions with various medical products and improving clinical results. The company operates in various business segments such as Acute Care Therapies, Life Sciences, Surgical Workflows, Group Functions, out of which Acute Care Therapies is the market-focused segment. The company offers a wide range of product categories such as Intensive Care, Cardiovascular Procedures, Operating Room, Sterile Reprocessing, Digital Health, Pharmaceutical Production, and Research Laboratories, out of which Intensive Care is the market-focused category.

• In October 2020, Getinge AB Added new features in mechanical ventilation called NAVA- Neurally Adjusted Ventilatory Assist. NAVA can help all types of patients breathe, from tiny premature babies weighing a few hundred grams to frail older patients. This has helped the company to increase its revenue in the market

The company has a wide global presence across the Middle East and Africa, Europe, Americas, and Asia with its various subsidiaries such as Getinge Australia Pty Ltd., (Australia), Getinge Belgium NV. (Belgium), Getinge do Brasil (Brazil), Equipamentos Medicos Ltda Maquet Colombia S.A.S. (Colombia), Getinge France S.A.S. (France), among others.